NewsRoom Articles - Page 879 of 1417

TuesdayMar 19, 2019 1:30 pm

Resideo Technologies Inc. (NYSE: REZI) Attends 31st Annual ROTH Conference

Resideo Technologies (NYSE: REZI) is a global provider of critical comfort and security solutions primarily in residential environments, and distributor of low-voltage and security products. Resideo has a presence in more than 150 million homes, with 15 million systems installed in homes each year. The company has a 40-year, exclusive license to use the Honeywell Home brand for products and will continue to serve more than 100,000 contractors through its ADI Global Distribution business, which exports to more than 100 countries from more than 200 stocking locations around the world. For more information, visit the company's website at www.resideo.com. About…

TuesdayMar 19, 2019 1:30 pm

Research Solutions Inc. (RSSS) Attends 31st Annual ROTH Conference

Research Solutions (OTCQB: RSSS) provides workflow efficiency solutions for R&D-driven organizations in life sciences, technology and academia worldwide. The company’s Software-as-a-Service platform provides tools or "Gadgets" that allow users to discover, access, manage and collaborate around science, technology and medical (STM) content and data. The company’s customers range from 70 percent of the top 25 global pharmaceutical companies to emerging small and medium-sized businesses. Research Solutions generates recurring revenue from subscriptions to its SaaS platform and transactional revenue from the sale of STM content. For more information, visit the company's website at www.researchsolutions.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial…

TuesdayMar 19, 2019 1:30 pm

Research Frontiers Inc. (NASDAQ: REFR) Attends 31st Annual ROTH Conference

Research Frontiers (NASDAQ: REFR) is a technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to over 40 companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, visit the company's website at www.SmartGlass.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial…

TuesdayMar 19, 2019 1:30 pm

CynergisTek Inc. (NYSE American: CTEK) Attends 31st Annual ROTH Conference

CynergisTek (NYSE American: CTEK) is a top-ranked cybersecurity firm dedicated to serving the information assurance needs of the healthcare industry. CynergisTek offers specialized services and solutions to help organizations achieve security, privacy, compliance, and document output goals. Since 2004, the company has served as a partner to hundreds of healthcare organizations and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been recognized by KLAS in the 2016 and 2018 Cybersecurity reports as a top performing firm in healthcare cybersecurity as well as the 2017 Best in KLAS winner for Cybersecurity Advisory…

TuesdayMar 19, 2019 1:30 pm

Renewable Energy Group Inc. (NASDAQ: REGI) Attends 31st Annual ROTH Conference

Renewable Energy Group (NASDAQ: REGI) is a provider of cleaner, lower carbon intensity products and services. The company is an international producer of biomass-based diesel, a developer of renewable chemicals and North America's largest producer of advanced biofuel. REG utilizes an integrated procurement, distribution, and logistics network to convert natural fats, oils, greases, and sugars into lower carbon intensity products. With 14 active biorefineries, a feedstock processing facility, research and development capabilities and a diverse and growing intellectual property portfolio, REG is committed to being a long-term leader in bio-based fuel and chemicals. For more information, visit the company's website…

TuesdayMar 19, 2019 1:30 pm

CymaBay Therapeutics Inc. (NASDAQ: CBAY) Attends 31st Annual ROTH Conference

CymaBay Therapeutics (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently conducting a phase 3 study of seladelpar for PBC and a phase 2b study of seladelpar for NASH. For more information, visit the company's website at www.cymabay.com. About NetworkNewsWire NetworkNewsWire (NNW) is…

TuesdayMar 19, 2019 1:30 pm

ReneSola Ltd. (NYSE: SOL) Attends 31st Annual ROTH Conference

ReneSola (NYSE: SOL) is a leading international manufacturer and supplier of green energy products. Leveraging its global presence with offices and warehouses in more than 16 countries and expansive production facilities and sales network, ReneSola is well-positioned to provide the highest quality green energy products and on-time services for EPC, installers and green energy projects around the world. ReneSola is focused on improving production efficiency and continually developing new product lines to provide additional value to its portfolio of green energy offerings. The company has expanded into energy storage solutions and energy efficient lighting, among other product categories. For more…

TuesdayMar 19, 2019 1:30 pm

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) Attends 31st Annual ROTH Conference

Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies. The DNA damage response program is evaluating a combination of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers and sapacitabine and olaparib, a PARP inhibitor, in BRCA positive patients with breast cancer. For more information, visit the company's…

TuesdayMar 19, 2019 1:30 pm

Daqo New Energy Corp. (NYSE: DQ) Attends 31st Annual ROTH Conference

Daqo New Energy (NYSE: DQ) is a manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2008, the company is one of the world’s lowest cost producers of high-purity polysilicon. Daqo’s highly efficient and technically advanced manufacturing facility in Xinjiang, China, currently has an annual polysilicon production capacity of 30,000 metric tons, and the company is undergoing a debottlenecking project and a capacity expansion project and expects to increase its annual polysilicon production capacity to 70,000 metric tons in the first quarter of 2020. For more information, visit the company's website at www.dqsolar.com. About NetworkNewsWire NetworkNewsWire (NNW)…

TuesdayMar 19, 2019 1:30 pm

Cytori Therapeutics Inc. (NASDAQ: CYTX) Attends 31st Annual ROTH Conference

Cytori Therapeutics (NASDAQ: CYTX) is developing, manufacturing and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine and Cell Therapy franchises, respectively. Cytori Nanomedicine is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. Cytori Cell Therapy, prepared within several hours with the proprietary Celution System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. For more…